Want to see ICCM full AI Analyst Report?
ICCM Stock Chart & Stats
$2.29
-$0.13(-4.22%)
At close: 4:00 PM EDT
$2.29
-$0.13(-4.22%)
Day’s Range― - ―
52-Week Range$0.96 - $25.63
Previous CloseN/A
Volume71.33K
Average Volume (3M)161.11K
Market Cap
$3.60M
Enterprise Value$4.71M
Total Cash (Recent Filing)$12.03M
Total Debt (Recent Filing)$90.00K
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Nov 25, 2026EPS Estimate
-1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.72
Shares Outstanding3,426,715
10 Day Avg. Volume219,692
30 Day Avg. Volume161,107
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)4.28
Price to Sales (P/S)11.48
P/FCF Ratio-2.65
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue1.19
Enterprise Value/Gross Profit3.31
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$10.00Price Target Upside336.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.57
Revenue Forecast (FY)$4.53M
Bulls Say, Bears Say
Bulls Say
Commercial TractionRapid revenue growth alongside a 70% expansion in the active U.S. installed base indicates improving physician and site adoption. Rising disposable probe utilization also adds a recurring-use component, supporting a potentially more durable commercial model as utilization expands.
China Market ExpansionRegulatory clearance in China expands the company’s addressable market beyond existing geographies and creates a pathway for future system and disposable-probe sales. Commercial access to a large healthcare market could strengthen IceCure’s international growth platform over time.
Clinical ValidationLonger-term clinical data, peer-reviewed publications, and inclusion in a specialist resource guide can improve physician confidence and support adoption. This evidence base may also help the company pursue broader guideline recognition and strengthen its position in minimally invasive tumor treatment.
Bears Say
Persistent Cash BurnContinued negative operating and free cash flow means the business is not yet funding operations internally. Persistent losses can require additional financing, constrain investment flexibility, and increase dependence on external capital while commercial scale and operating leverage remain unproven.
Reimbursement UncertaintyRemaining under a temporary Category III code leaves a key reimbursement milestone unresolved and may slow provider adoption or create uncertainty in procedure economics. IceCure must continue building evidence and engaging medical societies before a potential 2027 resubmission.
Potential DilutionExpanding the equity incentive reserve increases the pool of shares that could be issued to employees and may dilute existing holders over time. Although intended to support recruitment and retention, equity-based compensation adds complexity while the company remains loss-making and capital dependent.
Icecure Medical News
ICCM FAQ
What was IceCure Medical’s price range in the past 12 months?
IceCure Medical lowest stock price was $0.96 and its highest was $25.63 in the past 12 months.
What is IceCure Medical’s market cap?
IceCure Medical’s market cap is $3.60M.
When is IceCure Medical’s upcoming earnings report date?
IceCure Medical’s upcoming earnings report date is Nov 25, 2026 which is in 35 days.
How were IceCure Medical’s earnings last quarter?
IceCure Medical released its earnings results on Aug 12, 2026. The company reported -$1.545 earnings per share for the quarter, missing the consensus estimate of -$1.517 by -$0.028.
Is IceCure Medical overvalued?
According to Wall Street analysts IceCure Medical’s price is currently Undervalued.
Does IceCure Medical pay dividends?
IceCure Medical does not currently pay dividends.
What is IceCure Medical’s EPS estimate?
IceCure Medical’s EPS estimate is -1.16.
How many shares outstanding does IceCure Medical have?
IceCure Medical has 3,426,715 shares outstanding.
What happened to IceCure Medical’s price movement after its last earnings report?
IceCure Medical reported an EPS of -$1.545 in its last earnings report, missing expectations of -$1.517. Following the earnings report the stock price went down -11.538%.
Which hedge fund is a major shareholder of IceCure Medical?
Currently, no hedge funds are holding shares in ICCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IceCure Medical
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
ICCM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive growth story: significant top‑line growth (≈45% YoY), meaningful expansion of the U.S. commercial installed base (~70% growth, >30 active sites), rising recurring utilization, positive clinical results and publications, and a strengthened cash position (~$12M) after financing. These operational and clinical advances are tempered by an increased net loss (H1 2026: $8.8M), higher operating expenses to fund commercialization and R&D, foreign exchange headwinds that compressed margins, and remaining uncertainty around reimbursement timelines and CHOICE enrollment timing. On balance, the company appears to be transitioning into a commercial growth phase with near‑term execution and reimbursement risks that are being actively managed.View all ICCM earnings summariesICCM Stock 12 Month Forecast
Average Price Target
$10.00
▲(336.68% Upside)
Technical Analysis
Ownership Overview
19.28% Insiders
1.18% Mutual Funds
0.58% Other Institutional Investors
78.96% Public Companies and
Individual Investors